dismiss

Garage Sale Auctions: Over 700 lots are available for a LIMITED TIME ONLY...starting at just $1! Click here to bid now!

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Oncology Homepage

Researchers develop AI approach for high-risk clinical tumor volumes Assisting low- and middle-income countries that lack contouring expertise

Dr. Benjamin Movsas American Radium Society Names president-elect

Tennessee governor vetoes state employee proton therapy coverage Would require PT to be covered under the same aggregate amount as IMRT

European medical center first to perform linac-based MR-guided RT using on-table adaptation Made possible with ViewRay's MRIdian Linac

Hospital in Italy performs radiosurgery with Brainlab's Elements Spine SRS software Automatically plans treatments for complex parts of the body

AI approach used to study Mars now assessing tumor response to therapies Could reduce sample sizes and accelerate process for approval of cancer therapies

Thermal imaging in development could provide real-time ablation views Taking guesswork and additional imaging out of the equation

PPI to purchase Elekta MR-linac systems for £25 million Will install at five cancer centers across the UK

Dr. Nancy P. Mendenhall Medical Director of UF Health Proton Therapy selected by University of Florida as 2018 Clinical Science Researcher of the Year

ViewRay showcases enhancements to MRIdian Linac system at ESTRO Will offer MR pulse sequencing capabilities

Courtesy of Dr. Neeta Pandit-Taskar
and Dr. Michael J. Morris

New PET imaging agent detects metastatic prostate cancer

by Lauren Dubinsky , Senior Reporter
Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December issue of The Journal of Nuclear Medicine.

With an estimated 1.1 million new cases and over 300,000 deaths annually from prostate cancer, it is the second most common cancer among men globally, according to the World Health Organization.

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras



X-ray, CT and MR are traditionally used to determine if prostate cancer has spread to other areas of the body, but it’s often a challenge to image. With this new molecular imaging approach, researchers have shown they can target both bone and soft tissue lesions.

The radiotracer combines a small amount of the radioactive material zirconium-89 with a fragment of an antibody called a minibody. The minibody has anti-prostate-specific membrane antigen qualities that cause it to attach to prostate cancer cells that traveled in the body.

PET then detects the particles that are emitted from the site and the resulting image shows the "hot spots" of PSMA overexpression. This method can detect prostate cancer cells that have metastasized to bone, which is the most difficult to find with standard approaches.

For the study, the researchers imaged 18 patients with new imaging agent, using PET/CT. They also conducted CT, MR, molecular bone and FDG-PET exams and then selected and biopsied the suspected disease sites.

They found the Zr-89-Df-IAB2M PET scans were positive in 17 of the patients with bone lesions found in nine and soft tissue disease found in 14.

The bone scans conducted with Tc-99m-methylene diphosphonate and FDG were positive for bone lesions in nine and six patients, respectively. CT and FDG scans were positive for soft tissue disease in 14 and 10 patients, respectively.

In two of the patients, a single site of disease in each patient was found only by Zr-89-Df-IAB2M. In total, the new agent detected 147 bone and 82 soft tissue lesions.

The researchers are hoping that once this approach is further developed, it will help to detect metastatic prostate cancer earlier and more accurately. They believe that after further validation, the agent may be used for targeted biopsies and even targeted radiotherapy.

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED